UCLA Receives Nearly $14 Million from NIH to Investigate Gene Therapy to Combat HIV

UCLA researchers and colleagues have received a $13.65 million grant from the National Institutes of Health (NIH) to investigate and further develop an immunotherapy known as CAR T, which uses genetically modified stem cells to target and destroy HIV.
[University of California, Los Angeles]
Press Release

Continue reading “UCLA Receives Nearly $14 Million from NIH to Investigate Gene Therapy to Combat HIV”

Bookmark

No account yet? Register

0
Share

Partner Therapeutics Announces Initiation of Clinical Trial Evaluating Leukine® in T Cell Replete HLA-mismatched Haploidentical Stem Cell Transplant

Partner Therapeutics announced the enrollment of the first patient dosed in a Phase II investigator-initiated study evaluating the efficacy and safety of Leukine® in T cell replete HLA-mismatched haploidentical stem cell transplant recipients who are receiving post-transplant cyclophosphamide.
[Partner Therapeutics, Inc.]
Press Release

Continue reading “Partner Therapeutics Announces Initiation of Clinical Trial Evaluating Leukine® in T Cell Replete HLA-mismatched Haploidentical Stem Cell Transplant”

Bookmark

No account yet? Register

0
Share

Curis Announces FDA Clearance of IND Application for CI-8993, the First-In-Class Monoclonal Anti-VISTA Antibody

Curis, Inc. announced that the FDA has cleared its Investigational New Drug (IND) application for CI-8993, the first-in-class monoclonal anti-VISTA antibody.
[Curis, Inc.]
Press Release

Continue reading “Curis Announces FDA Clearance of IND Application for CI-8993, the First-In-Class Monoclonal Anti-VISTA Antibody”

Bookmark

No account yet? Register

0
Share

ECU, Vidant Begin Trial of COVID-19 Treatment

Dr. Paul Cook, chief of the Division of Infectious Diseases at East Carolina Univesity’s Brody School of Medicine, began enrolling patients June 1 in a clinical trial investigating a new treatment aimed at preventing and shortening the duration of Acute Respiratory Distress Syndrome (ARDS). ARDS is a characteristic of COVID-19 that occurs when fluid builds up in the lungs and prevents oxygen from entering the bloodstream.
[East Carolina University]
Full Article

Continue reading “ECU, Vidant Begin Trial of COVID-19 Treatment”

Bookmark

No account yet? Register

0
Share

FDA Just Gave a Thumbs Down to Trump’s Favorite COVID-19 Drugs

The FDA revoked its emergency use authorization for hydroxychloroquine sulfate and chloroquine phosphate to treat COVID-19.
[ScienceInsider]
Press Release

Continue reading “FDA Just Gave a Thumbs Down to Trump’s Favorite COVID-19 Drugs”

Bookmark

No account yet? Register

0
Share

Hong Kong’s Contentious National Security Law Concerns Some Academics

China’s plan to introduce a new security law in Hong Kong has prompted mixed reactions from scientists there. Some fear that such a law could lead to government interference in research, restrict participation in international collaborations and increase self-censorship, whereas others are confident that research will be unaffected.
[Nature News]
Editorial

Continue reading “Hong Kong’s Contentious National Security Law Concerns Some Academics”

Bookmark

No account yet? Register

0
Share

City of Hope Signs Licensing Agreement with Scopus BioPharma Inc. to Develop Novel, Targeted Immuno-Oncology Gene Therapy

City of Hope have signed an exclusive, worldwide licensing agreement with Scopus BioPharma Inc. Scopus will further develop and plans to commercialize a City of Hope first-in-class, targeted immuno-oncology gene therapy.
[City of Hope]
Press Release

Continue reading “City of Hope Signs Licensing Agreement with Scopus BioPharma Inc. to Develop Novel, Targeted Immuno-Oncology Gene Therapy”

Bookmark

No account yet? Register

0
Share

Ovid Therapeutics Announces Strategic Research Collaboration Focused on Accelerating the Development of New Treatments for Rare Neurological Diseases

Ovid Therapeutics Inc. announced a strategic research collaboration with Columbia University Irving Medical Center researchers to advance genetic based therapies for a range of rare neurological conditions, complementary to Ovid’s current pipeline.
[Ovid Therapeutics Inc.]
Press Release

Continue reading “Ovid Therapeutics Announces Strategic Research Collaboration Focused on Accelerating the Development of New Treatments for Rare Neurological Diseases”

Bookmark

No account yet? Register

0
Share

FDA Just Gave a Thumbs Down to Trump’s Favorite COVID-19 Drugs

The FDA revoked its emergency use authorization for hydroxychloroquine sulfate and chloroquine phosphate to treat COVID-19.
[ScienceInsider]
Press Release

Continue reading “FDA Just Gave a Thumbs Down to Trump’s Favorite COVID-19 Drugs”

Bookmark

No account yet? Register

0
Share

Sarepta Therapeutics Announces Positive Expression and Functional Data From the SRP-9003 Gene Therapy Trial to Treat Limb-Girdle Muscular Dystrophy Type 2E

Sarepta Therapeutics announced positive results from a study of SRP-9003, its investigational gene therapy for limb-girdle muscular dystrophy Type 2E.
[Sarepta Therapeutics]
Abstract

Continue reading “Sarepta Therapeutics Announces Positive Expression and Functional Data From the SRP-9003 Gene Therapy Trial to Treat Limb-Girdle Muscular Dystrophy Type 2E”

Bookmark

No account yet? Register

0
Share

New Wound-Healing Research Project Wins NASA Tick of Approval

A group of Australian scientists have caught the attention of NASA with a novel technology development that could potentially heal wounds in days rather than weeks without using stitches.
[Southern Cross University]
New wound-healing research project wins NASA tick of approval - Southern Cross University. (n.d.). Retrieved June 12, 2020, from https://www.scu.edu.au/engage/news/2020/new-wound-healing-research-project-wins-nasa-tick-of-approval.php Cite
Press Release

Continue reading “New Wound-Healing Research Project Wins NASA Tick of Approval”

Bookmark

No account yet? Register

0
Share

International Prize Awarded to Two Pieces of Novel Research in the 3Rs

The 2019 3Rs prize has been jointly awarded to Dr Francesca Nunn and Dr Marta Shahbazi. Marta and colleagues have developed advanced 3D cultures of human and mouse ESCs to mimic the development of the embryo at implantation and the subsequent morphogenesis and formation of the amniotic cavity.
[EurekAlert!]
Press Release

Continue reading “International Prize Awarded to Two Pieces of Novel Research in the 3Rs”

Bookmark

No account yet? Register

0
Share
Share